Frontage Laboratories, Inc. officially unveiled its newest Contract Research, Development and Manufacturing Organization (CRDMO) facility during a grand open house event held on May 22, 2025, at its campus in Exton, Pennsylvania. The launch of the 46,300-square-foot Good Manufacturing Practice (GMP) facility located at 240 Sierra Drive marks a significant expansion of the company's manufacturing capabilities.
Advanced Manufacturing Infrastructure
The new facility features nine GMP suites designed to support diverse pharmaceutical manufacturing needs: two high-potent suites, two aseptic suites, and five non-sterile suites. This configuration enables manufacturing of injectables, tablets, capsules, creams, gels, ointments, ophthalmic and nasal preparations. The facility also houses two formulation development labs and three analytical labs, including a specialized micro lab.
According to the company, this infrastructure provides a comprehensive, one-stop-shop solution for pharmaceutical and biotech clients covering all aspects of clinical supplies, including formulation development, manufacturing, analytical testing, packaging, labelling, distribution, and storage.
Strategic Expansion Initiative
"The grand opening of this new CRDMO marks a significant milestone for us in the CDMO and clinical trial material supply space," said Dr. Song Li, Founder and Executive Chairman of Frontage. Dr. Wentao Zhang, Co-CEO of Frontage Laboratories, emphasized the strategic importance of the expansion: "The launch of our new state-of-the-art CDMO facility significantly enhances our manufacturing capabilities, positioning us closer to our clients and enabling us to respond more efficiently to their evolving development and supply needs."
The expansion complements Frontage's existing service offerings, which include drug substance synthesis, DMPK, safety & toxicology studies, bioanalysis, and clinical trial support.
Global Operations and Experience
Frontage Laboratories, Inc., a wholly owned subsidiary of Frontage Holdings Corporation (HKEX: 1521.HK), operates as a US-based global CRDMO offering end-to-end integrated product development services from drug discovery through late-phase clinical trials and manufacturing. With over 25 years of experience, the company supports pharmaceutical and biotech companies across multiple service areas including drug discovery, API synthesis, DMPK, safety and toxicology, formulation development, GMP manufacturing, analytical services, clinical trials, bioanalytical services and central lab operations.
The company operates 26 sites worldwide and has played a pivotal role in helping clients secure regulatory approvals across the US, Canada, Europe, and Asia. This new Pennsylvania facility represents part of Frontage's ongoing expansion strategy, which Dr. Zhang noted has involved "opening new sites and acquiring existing ones" over recent years.
